Craft

Sorrento Therapeutics

Stock Price

$0

2024-07-03

Market Capitalization

$3.4 M

2024-07-03

Revenue

$62.8 M

FY, 2022

Sorrento Therapeutics Summary

Company Summary

Overview
Sorrento Therapeutics is a biopharmaceutical company engaged in the acquisition, discovery, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs. Sorrento's primary therapeutic focus is cancer although its products and technologies have much broader clinical applications including autoimmune disorders, metabolic diseases and infectious diseases. The Company's lead programs consist of four Phase III BioSimilar/BioBetter antibodies. It is also advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs).
Type
Public
Status
Active
Founded
2006
HQ
San Diego, CA, US | view all locations
Website
http://sorrentotherapeutics.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Henry Ji

    Henry Ji, Chairman, President and CEO

    • Mike Royal

      Mike Royal, Chief Medical Officer

      • David Lemus, Director

        • Mark R. Brunswick

          Mark R. Brunswick, Senior Vice President, Regulatory Affairs

        LocationsView all

        2 locations detected

        • San Diego, CA HQ

          United States

          4955 Directors Pl

        • San Diego, CA

          United States

          9380 Judicial Dr

        Sorrento Therapeutics Financials

        Summary Financials

        Cash (Q2, 2023)
        $69.7M
        Enterprise value
        $78.4M

        Footer menu